Device Trial Radar · NCT06680427
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 26, 2025
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- MiRusNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
Conditions
- Aortic Stenosis Symptomatic
Interventions
Siegel Transcatheter Aortic Valve (TAVR)Device
Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Technical success of implantation of the Siegel TAVRTime frame: Immediate post procedure
- All-cause mortality or disabling strokeTime frame: 30 Days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Stanford
Palo Alto, California
NCH Healthcare System
Naples, Florida
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.